Postpartum Depression and the Missed Hand-Off to Primary Care
May 17, 2025

ACOG 2025: Joy Baker, MD, called for stronger cross-specialty collaboration to address maternal mental health after birth.

ACOG 2025: Steven Fleischman, MD, Inaugurated as 76th President, Urges New Fellows to Lead with Purpose
May 17, 2025

Steven Fleischman, MD, was inaugurated as ACOG’s 76th president, urging new fellows to lead with purpose and recognize their value in women’s health care.

FDA Clears First Plasma-Based Assay to Aid Alzheimer Disease Diagnosis
May 17, 2025

The diagnostic is designed to help clinicians determine the likelihood of cerebral β-amyloid plaque deposition, one of the neuropathologic hallmarks of AD.

Primary Care Falls Short in Managing Adolescent Heavy Menstrual Bleeding, Researchers Warn
May 17, 2025

Fewer than half of young girls who experienced heavy menstrual bleeding were given hormonal treatment and far fewer were referred to gynecology, authors reported.

GLP1-RAs Superior to Metformin for CVD Risk Reduction in Women with PCOS, Large Study Finds
May 17, 2025

The findings support the potential cardiovascular advantages of the GLP-1RA class in women with PCOS, a population already at increased cardiometabolic risk.

Study Identifies 6 Components of a Pregnancy Exercise Program that Reduce Risk of Poor Perinatal Outcomes
May 17, 2025

While exercise is beneficial during pregnancy and ACOG recommends 150 mins/week, this is the first study to examine benefits of specific regimen elements on their own.

Fezolinetant Demonstrates Reduced Waist Circumference, Body Roundness and Stable Weight and BMI in 52-Week Pooled Analysis of Phase 3 SKYLIGHT Trials
May 17, 2025

Postmenopausal women taking fezolinetant experienced positive changes in body fat distribution, increases in which are known to increase risks of cardiometabolic disease.

ACOG 2025: Poster Highlights for Primary Care
May 16, 2025

Details on 12 key abstracts with clinical relevance for primary care, from menopause management to PPD screening and HPV testing.

Elinzanetant Demonstrates Clinically Meaningful Reductions in Menopausal Vasomotor Symptoms, Meta-analysis Shows
May 16, 2025

Elinzanetant reduced VMS frequency and intensity, and improved sleep and quality of life, according to the meta-analysis to be presented at the ACOG 2025 meeting.